Literature DB >> 8778034

Malaria: a tumour necrosis factor inhibitor from parasitized erythrocytes.

N A Sheikh1, H N Caro, J Taverne, J H Playfair, T W Rademacher.   

Abstract

The excessive production of tumour necrosis factor (TNF) is associated with the pathology of blood-stage malaria and phosphatidylinositol-containing phospholipid antigens from parasitized erythrocytes stimulate its secretion by macrophages, thus acting as toxins. This brief report describes some properties of an inhibitor present in lysates from erythrocytes infected with malarial parasites that blocked the detection of recombinant TNF in an enzyme-linked immunosorbent assay and diminished or abolished the cytotoxicity of TNF. It was not found in control lysates of normal erythrocytes. Its addition to macrophage cultures stimulated by toxic malarial preparations or by bacterial lipopolysaccharide also blocked the detection of TNF. These findings may explain the contradictory results obtained from different assays for TNF, and emphasize the need for caution when interpreting the results of a single assay system. If released when parasitized erythrocytes rupture in vivo, the inhibitor could help protect both parasite and host from the damaging effects of TNF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8778034      PMCID: PMC1384117     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing anti-tumor necrosis factor antibodies.

Authors:  R J Debs; N Düzgüneş; E N Brunette; B Fendly; J Patton; R Philip
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

2.  Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.

Authors:  K C Sheehan; N H Ruddle; R D Schreiber
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

3.  Human recombinant tumor necrosis factor alpha protects susceptible A/J mice against lethal Plasmodium chabaudi AS infection.

Authors:  M M Stevenson; E Ghadirian
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

4.  Recombinant tumour necrosis factor inhibits malaria parasites in vivo but not in vitro.

Authors:  J Taverne; J Tavernier; W Fiers; J H Playfair
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

5.  Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria.

Authors:  P Kern; C J Hemmer; J Van Damme; H J Gruss; M Dietrich
Journal:  Am J Med       Date:  1989-08       Impact factor: 4.965

6.  Malarial parasites induce TNF production by macrophages.

Authors:  C A Bate; J Taverne; J H Playfair
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

7.  Stimulators of tumour necrosis factor production released by damaged erythrocytes.

Authors:  C A Bate; D P Kwiatkowski
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

8.  Malaria exoantigens induce T-independent antibody that blocks their ability to induce TNF.

Authors:  C A Bate; J Taverne; A Davé; J H Playfair
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

9.  Tumor necrosis factor and disease severity in children with falciparum malaria.

Authors:  G E Grau; T E Taylor; M E Molyneux; J J Wirima; P Vassalli; M Hommel; P H Lambert
Journal:  N Engl J Med       Date:  1989-06-15       Impact factor: 91.245

10.  Soluble malarial antigens are toxic and induce the production of tumour necrosis factor in vivo.

Authors:  C A Bate; J Taverne; J H Playfair
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

View more
  1 in total

1.  Fatty acids from Plasmodium falciparum down-regulate the toxic activity of malaria glycosylphosphatidylinositols.

Authors:  Françoise Debierre-Grockiego; Louis Schofield; Nahid Azzouz; Jörg Schmidt; Cristiana Santos de Macedo; Michael A J Ferguson; Ralph T Schwarz
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.